190 related articles for article (PubMed ID: 25815218)
21. Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy.
Mazzaro C; Dal Maso L; Mauro E; Visentini M; Tonizzo M; Gattei V; Andreone P; Pozzato G
Autoimmun Rev; 2020 Aug; 19(8):102589. PubMed ID: 32540448
[TBL] [Abstract][Full Text] [Related]
22. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
[TBL] [Abstract][Full Text] [Related]
23. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.
Gragnani L; Fognani E; Piluso A; Boldrini B; Urraro T; Fabbrizzi A; Stasi C; Ranieri J; Monti M; Arena U; Iannacone C; Laffi G; Zignego AL;
Hepatology; 2015 Apr; 61(4):1145-53. PubMed ID: 25431357
[TBL] [Abstract][Full Text] [Related]
24. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
Naik GS; Tyagi MG
J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
[TBL] [Abstract][Full Text] [Related]
25. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.
Lamprecht P; Lerin-Lozano C; Merz H; Dennin RH; Gause A; Voswinkel J; Peters SO; Gutzeit O; Arlt AC; Solbach W; Gross WL
Ann Rheum Dis; 2003 Dec; 62(12):1230-3. PubMed ID: 14644867
[TBL] [Abstract][Full Text] [Related]
26. [Autoimmune and lymphoproliferative HCV-correlated manifestations: example of mixed cryoglobulinaemia (review)].
Ghinoi A; Mascia MT; Puccini R; Ferri C
G Ital Nefrol; 2004; 21(3):225-37. PubMed ID: 15285001
[TBL] [Abstract][Full Text] [Related]
27. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Delluc A; Piette JC; Cacoub P
Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
[TBL] [Abstract][Full Text] [Related]
28. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
29. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies.
Garini G; Allegri L; Vaglio A; Buzio C
Ann Ital Med Int; 2005; 20(2):71-80. PubMed ID: 16052839
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.
Cachay ER; Wyles D; Hill L; Ballard C; Torriani F; Colwell B; Kuo A; Schooley R; Mathews CW
Open Forum Infect Dis; 2015 Dec; 2(4):ofv168. PubMed ID: 26697509
[TBL] [Abstract][Full Text] [Related]
32. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
33. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
[TBL] [Abstract][Full Text] [Related]
34. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
Pol S; Sulkowski MS; Hassanein T; Gane EJ; Liu L; Mo H; Doehle B; Kanwar B; Brainard D; Subramanian GM; Symonds WT; McHutchison JG; Nahass RG; Bennett M; Jacobson IM
Hepatology; 2015 Jul; 62(1):129-34. PubMed ID: 25847509
[TBL] [Abstract][Full Text] [Related]
35. Etiologic treatment of hepatitis C virus-associated mixed cryoglobulinemia.
Mazzaro C; Pozzato G; Zorat F; Baragiotta AM; Biscontin MG; Spina M; Tirelli U
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S102-6. PubMed ID: 17936209
[TBL] [Abstract][Full Text] [Related]
36. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
Terrier B; Saadoun D; Sène D; Sellam J; Pérard L; Coppéré B; Karras A; Blanc F; Buchler M; Plaisier E; Ghillani P; Rosenzwajg M; Cacoub P
Arthritis Rheum; 2009 Aug; 60(8):2531-40. PubMed ID: 19644879
[TBL] [Abstract][Full Text] [Related]
38. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
39. Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence.
Fabrizi F; Cerutti R; Porata G; Messa P; Ridruejo E
Pathogens; 2019 Oct; 8(4):. PubMed ID: 31590268
[TBL] [Abstract][Full Text] [Related]
40. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
